Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Pharmacokinetics and food effect: PRAX-562-101 healthy-volunteer study

“time to observed maximum concentration (tmax) between 2 and 3 hours.” (opens the source at this quote in a new tab)

“PRAX-562 can be administered without regard to food.” (opens the source at this quote in a new tab)

Pharmacokinetics and metabolism: EILAT XVIII progress report

“Relutrigine has a prolonged half-life (median ~110 h in pediatric patients; 129 h in adults)” (opens the source at this quote in a new tab)

“Metabolism is mediated predominantly by CYP1A2.” (opens the source at this quote in a new tab)